-
Ad hoc announcement pursuant to Art. 53 LRReimagine MedicineAd Hoc
-
Ad hoc announcement pursuant to Art. 53 LRReimagine MedicineDrug DevelopmentAd Hoc
-
Ad hoc announcement pursuant to Art. 53 LRReimagine MedicineAd Hoc
-
Ad-hoc-Mitteilung gemäss Art. 53 KRAd Hoc
-
Ad hoc announcement pursuant to Art. 53 LRAd Hoc
-
Ad-hoc-Mitteilung gemäss Art. 53 KRReimagine MedicineMedical InnovationsInnovationAd Hoc
-
Annonce événementielle selon l’art. 53 RCReimagine MedicineMedical InnovationsInnovationAd Hoc
-
Ad hoc announcement pursuant to Art. 53 LRReimagine MedicineMedical InnovationsInnovationAd Hoc
-
Ad hoc announcement pursuant to Art. 53 LRReimagine MedicineOncologyMedical InnovationsCancerAd Hoc
-
Basel, June 28, 2021 — Novartis announced today the appointment of Rob Kowalski, Pharm.D., Global Head Regulatory Affairs and US Head of Drug Development as Chief People & Organization Officer. He will report to Vas Narasimhan, M.D., CEO of Novartis and become a member of the Executive Committee of Novartis (ECN), effective September 1,…CareersAd Hoc
-
Ad-hoc-Mitteilung gemäss Art. 53 KRReimagine MedicineInnovationAd Hoc
-
Annonce événementielle selon l’art. 53 RCReimagine MedicineInnovationAd Hoc